Cleveland BioLabs in brief
Cleveland BioLabs is an unlisted company in the Biotechnology industry, based in Buffalo, USA. It was founded in 2003. In the year to December 2021 it had sales of $1 M and a net loss of $102 M.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cleveland BioLabs
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies.
In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma".
Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Cleveland BioLabs timeline
- 2003
- 🏁· approximateFounded
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2006
- 🔔Initial public offering as Cleveland Biolabs IncFinal prospectus filed with the SEC on 21 July 2006; shares registered for exchange trading on 20 July 2006.
- 2021
- 💰Record revenue of $1 millionFY2021, the highest of the 3 years on record.
- ✎Renamed Cytocom, Inc.Formerly Cleveland Biolabs Inc.
- ✎Renamed Statera Biopharma, Inc.Formerly Cytocom, Inc..
Events of Cleveland BioLabs from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Cleveland BioLabs
- Acquisitions and changes
- Delisted: the exchange removed its shares from listing (Form 25-NSE) on 3 March 2023.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -6835.6%
- Operating margin
- -6600.0%
- Return on equity
- —
- Liabilities / assets
- 107.1%
- Net debt
- $9M
- Revenue growth
- +34.2%
- R&D / revenue
- 794.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2021 | $1M | — | $-98M | $-102M | -6835.6% |
| Dec 2020 | — | — | $-11M | $-12M | — |
| Dec 2019 | $1M | -2.6% | $-2M | $-3M | -238.7% |
| Dec 2018 | $1M | — | $-5M | $-4M | -316.7% |
| Dec 2017 | — | — | $-6M | $-10M | — |
| Dec 2016 | — | — | $-6M | $-3M | — |
| Dec 2015 | — | — | $-11M | $-13M | — |
| Dec 2014 | — | — | $-14M | $0M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2021 | $-28M | $0M | $-28M | — | — |
| Dec 2020 | $-5M | $0M | $-5M | $-0.19 | — |
| Dec 2019 | $-3M | — | — | $-0.23 | — |
| Dec 2018 | $-5M | — | — | $-0.32 | — |
| Dec 2017 | $-7M | — | — | $-0.87 | — |
| Dec 2016 | $-5M | — | — | $-0.24 | — |
| Dec 2015 | $-12M | — | — | $-1.79 | — |
| Dec 2014 | $-14M | — | — | $0.60 | — |
SEC filings
- Feb 27, 2023DEF 14AProxy statement
- Feb 1, 20238-KCurrent reportBylaws amended
- Jan 20, 20238-KCurrent reportListing notice
- Nov 28, 2022DEF 14AProxy statement
- Nov 15, 20228-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Nov 14, 202210-QQuarterly report · period to Sep 2022
- Nov 7, 20228-KCurrent reportMaterial agreement · Unregistered share sale
- Oct 28, 202210-QQuarterly report · period to Jun 2022
- Oct 27, 20228-KCurrent reportOther events
- Oct 24, 20228-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure
- Oct 21, 202210-QQuarterly report · period to Mar 2022
- Oct 17, 20228-KCurrent reportMaterial agreement · Listing notice
Official filings of Cleveland BioLabs with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-98 M
- Net income
- $-102 M
For year ending December-2021 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $23 M
- Total equity
- $-2 M
As of December-2021
Insider trading at Cleveland BioLabs#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Taunia MarkvickaChief Operating Officer, Director | Grant or award | +100,000 | — | — | 100,000 | Form 4 |
| filed | Randy S. SaluckDirector | Grant or award | +60,000 | — | — | 60,140 | Form 4 |
| filed | Steve K. BarbarickDirector | Grant or award | +60,000 | — | — | 60,000 | Form 4 |
| filed | Lea VernyDirector | Grant or award | +60,000 | — | — | 60,000 | Form 4 |
| filed | Michael K. HandleyPresident and CEO, Director | Grant or award | +296,609 | — | — | 296,609 | Form 4 |
| filed | Clifford SelskyChief Medical Officer | Grant or award | +101,579 | — | — | 101,579 | Form 4 |
| filed | Robert BuckheitChief Technology Officer | Grant or award | +24,378 | — | — | 24,378 | Form 4 |
| filed | Peter AronstamChief Financial Officer | Grant or award | +141,370 | — | — | 141,370 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cleveland BioLabs#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q1 2022 | Q1 2022 | $0.1M |
| Q1 2021 | Q1 2022 | $0M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cleveland BioLabs scorecard#
Passes 0 of the 5 checks that could be worked out. Fiscal year 2021.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$102 M-$102 M in fiscal 2021 against -$3 M in 2016.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$102 MNet income -$102 M in fiscal 2021.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2021.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.37 at the end of fiscal 2021.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2021.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cleveland BioLabs: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 | FY 2012to Dec 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.5—100% | 0r0.3−100%— | 1.1r0.9−2.2%100% | 1.1—100% | — | — | — | — | — | — | |
| Cost of revenue | 0.5—32.8% | 0—— | — | — | — | — | — | — | — | — | |
| Gross profit | 1.0—67.2% | 0—— | — | — | — | — | — | — | — | — | |
| Research and development | 12+125%796% | 5.3r0.7+218%— | 1.7−54.2%149% | 3.6−28.3%318% | 5.0−22.3%— | 6.5−9.1%— | 7.1−26.0%— | 9.7−50.6%— | 20−13.2%— | 23—— | |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | 11—— | |
| Selling and marketing | 0.1+3202%5.3% | 0.0—— | — | — | — | — | — | — | — | — | |
| General and administrative | 20+279%1334% | 5.2r2.2+188%— | 1.8−21.6%163% | 2.3−7.3%204% | 2.5−26.0%— | 3.4−46.9%— | 6.4−25.0%— | 8.5−29.6%— | 12+8.3%— | 11—— | |
| Operating expenses | 99+846%6681% | 11r2.8+202%— | 3.5−41.5%312% | 5.9−21.3%522% | 7.5−23.5%— | 9.9−26.9%— | 13−25.5%— | 18−42.6%— | 32−6.1%— | 34—— | |
| Operating income | −98—−6613% | −11r−2.6—— | −2.4r−2.6—−212% | −4.8—−422% | −5.6—— | −6.4—— | −11—— | −14—— | −23—— | −30—— | |
| Interest expense and finance costs | — | — | — | — | — | 0−100%— | 0.5−60.3%— | 1.3—— | — | — | |
| Share of profit of associates | — | — | — | — | — | 0—— | −0.4—— | −0.3—— | — | — | |
| Other non-operating income (expense) | −3.5—−237% | −1.6r0.1—— | −0.3r−0.6−131%−30.0% | 1.1—96.0% | −4.2−213%— | 3.8—— | −2.3−116%— | 14+390%— | 2.9−61.4%— | 7.6—— | |
| Income tax | 0—0.0% | 0—— | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Income from continuing operations | −36—−2431% | −12r−2.4—— | −2.7r−3.2—−242% | −3.7—−326% | −9.8—— | −2.6—— | −13−36985%— | 0.0—— | −20—— | −22—— | |
| Income from discontinued operations | 0.0—0.0% | 0—— | — | — | — | — | — | — | — | — | |
| Net income including minority interests | −102—−6851% | −12r−2.4—— | −2.7r−3.2—−242% | −3.7—−326% | −9.8—— | −2.6—— | −13−36985%— | 0.0—— | −20—— | −22—— | |
| Minority interests' share of net income | −0.0—−1.6% | 0r−0.0—— | −0.0—−4.3% | −0.1—−8.4% | −0.1−298%— | 0.1—— | −0.4—— | −1.6—— | −2.9—— | −4.2r4.2—— | |
| Net income attributable to shareholders | −102—−6849% | −12r−2.4—— | −2.6r−3.1—−238% | −3.6—−317% | — | — | — | — | −17—— | −18—— | |
| Earnings per share, basic | -2.90—— | -1.66r-0.19—— | -0.23r-0.28—— | -0.32—— | -0.87—— | -0.24—— | -1.79−398%— | 0.60—— | -7.67r-0.38—— | -9.75r-0.49—— | |
| Earnings per share, diluted | — | -0.19—— | -0.23r-0.28—— | -0.32—— | -0.87—— | -0.24—— | -1.79−398%— | 0.60—— | -7.67r-0.38—— | -0.49—— | |
| Shares, weighted average (basic) | 35+381%— | 7.3—— | — | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | 12+9.7%— | 11+0.0%— | 11+0.9%— | 11+1.9%— | 11+55.6%— | 7.1+161%— | 2.7+20.1%— | 2.3r45−94.0%— | 37—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 1.8+211%8.7% | 0.6r1.9−47.3%57.4% | 1.1−68.9%55.3% | 3.6−14.5%79.8% | 4.2−38.7%43.9% | 6.9+16.6%43.3% | 5.9+90.7%28.3% | 3.1−69.1%31.6% | 10−60.8%68.4% | 26—80.1% | |
| Short-term investments | 0.1—0.6% | 0r0.3−100%0.0% | 0.5−10.2%22.2% | 0.5−89.0%11.1% | 4.6−45.3%47.4% | 8.3−39.1%52.3% | 14—65.6% | — | — | 2.6—8.2% | |
| Receivables | 0.2—1.0% | 0r0.0−100%0.0% | 0.4+50.4%18.6% | 0.3−54.6%5.6% | 0.6+57.2%5.8% | 0.4−44.1%2.2% | 0.6+136%3.0% | 0.3−41.7%2.7% | 0.5+994%3.1% | 0.0—0.1% | |
| Other current assets | 0.8+32776%4.0% | 0.0r0.0−94.4%0.2% | 0.0−56.1%2.2% | 0.1−55.7%2.3% | 0.2−19.4%2.4% | 0.3−34.5%1.8% | 0.4+154%2.1% | 0.2−49.4%1.8% | 0.3−68.1%2.3% | 1.1—3.4% | |
| Current assets | 4.1+348%19.6% | 0.9r2.3−53.8%89.4% | 2.0−55.3%98.3% | 4.5−53.3%98.7% | 9.6−39.7%99.5% | 16−23.2%99.6% | 21+484%99.1% | 3.5−68.2%36.1% | 11−62.1%75.9% | 29—91.9% | |
| Property, plant and equipment | 0.2+2223%1.0% | 0.0r0.0−44.0%0.8% | 0.0−44.1%0.8% | 0.0+49.3%0.6% | 0.0−50.3%0.2% | 0.0−69.6%0.2% | 0.1−49.7%0.6% | 0.2−46.6%2.5% | 0.5−53.6%3.1% | 1.0—3.1% | |
| Right-of-use (leased) assets | 1.0+854%4.6% | 0.1—9.8% | — | — | — | — | — | — | — | — | |
| Goodwill | 9.3—43.8% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Other intangible assets | 1.6—7.5% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Investments in associates | — | — | — | — | — | — | 0−100%0.0% | 4.3—43.5% | — | — | |
| Total assets | 21+1944%100% | 1.0r2.3−49.2%100% | 2.0−55.1%100% | 4.5−52.9%100% | 9.6−39.7%100% | 16−23.6%100% | 21+113%100% | 9.8−33.2%100% | 15−54.1%100% | 32—100% | |
| Accounts payable | 4.0+249%18.7% | 1.1r0.2+331%110% | 0.3+89.5%12.9% | 0.1−30.9%3.1% | 0.2−40.1%2.1% | 0.3+70.7%2.1% | 0.2−81.4%0.9% | 1.1+33.2%10.8% | 0.8−47.9%5.4% | 1.5—4.8% | |
| Current liabilities | 11+143%53.1% | 4.6r0.3+339%446% | 1.1r1.5+15.4%51.7% | 0.9−58.8%20.1% | 2.2−28.8%23.0% | 3.1−46.8%19.5% | 5.8−10.5%28.0% | 6.5+9.1%66.5% | 6.0−47.6%40.7% | 11—35.7% | |
| Lease liabilities (non-current) | 0.8+1045%3.8% | 0.1—6.8% | — | — | — | — | — | — | — | — | |
| Non-current liabilities | — | — | — | 0.0+12.9%0.2% | 0.0—0.1% | — | — | — | — | — | |
| Total liabilities | 23+383%107% | 4.7r0.3+346%453% | 1.1r1.5+14.4%51.7% | 0.9−58.6%20.3% | 2.2−28.6%23.1% | 3.1−46.8%19.5% | 5.8−27.2%28.0% | 8.0−38.8%81.8% | 13+13.8%89.2% | 12—36.0% | |
| Retained earnings | −129—−612% | −169—−16331% | −167r−167—−8184% | −164—−3618% | −160—−1666% | −151—−945% | −148—−709% | −134—−1365% | −136—−922% | −118—−370% | |
| Shareholders' equity | −1.6—−7.4% | −3.0—−286% | −4.1r−4.5—−199% | −1.5−166%−32.0% | 2.2−70.8%22.8% | 7.5−23.9%47.2% | 9.9—47.4% | −1.6—−16.4% | −9.5−250%−64.8% | 6.3—19.8% | |
| Minority interests | 0.1−98.8%0.3% | 5.0−1.3%480% | 5.0−0.5%247% | 5.1−2.7%112% | 5.2−2.1%54.1% | 5.3+3.4%33.4% | 5.1+51.8%24.7% | 3.4−69.4%34.6% | 11−21.5%75.6% | 14—44.2% | |
| Total equity | −1.5−101%−7.1% | 143r2.0—13857% | −4.2r0.5−216%−207% | 3.6−51.2%79.7% | 7.4−42.3%76.9% | 13−14.6%80.5% | 15+742%72.0% | 1.8+13.0%18.2% | 1.6−92.3%10.8% | 20—64.0% | |
| Total liabilities and equity | 21+1944%100% | 1.0r2.3−49.2%100% | 2.0−55.1%100% | 4.5−52.9%100% | 9.6−39.7%100% | 16−23.6%100% | 21+113%100% | 9.8−33.2%100% | 15−54.1%100% | 32—100% | |
| Shares outstanding | 35+165%— | 13+18.4%— | 110.0%— | 11+0.2%— | 11+2.7%— | 110.0%— | 11+284%— | 2.9r2.9+26.5%— | 2.3r45−94.9%— | 45—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0.0−16.9%— | 0.0−24.2%1.2% | 0.0—1.6% | — | — | — | — | — | — | |
| Share-based compensation | 6.1+124%407% | 2.7r0.0—— | — | — | 0−100%— | 0.0−85.9%— | 0.1−80.6%— | 0.5−66.3%— | 1.5−41.9%— | 2.5—— | |
| Cash from operating activities | −28—−1896% | −5.1r−2.4—— | −2.7—−239% | −4.6—−405% | −6.6—— | −5.0—— | −12—— | −14r−14—— | −23—— | −21—— | |
| Capital expenditure | −0.2—−12.3% | −0.0—— | — | — | — | — | — | — | — | — | |
| Cash from investing activities | 13—905% | −0.0r0.1−106%— | 0.2−96.0%14.1% | 4.0+2.0%349% | 3.9−31.5%— | 5.7—— | −10—— | −1.8−419%— | 0.6−59.1%— | 1.4—— | |
| Debt issued | — | — | — | — | — | — | — | — | 7.3—— | — | |
| Shares issued | 7.3—494% | 0—— | — | — | — | 0−100%— | 27+180%— | 9.7—— | — | 16—— | |
| Cash from financing activities | 21+269%1411% | 5.7r3.2—— | — | 0.1—4.9% | 0−100%— | 0.5−97.8%— | 25+135%— | 11+45.8%— | 7.3−66.3%— | 22—— | |
| Exchange-rate effect on cash | — | −0.0−279%— | 0.0—1.4% | −0.0−142%−1.9% | 0.1—— | −0.2−181%— | 0.2—— | −1.3—— | −0.3−160%— | 0.5—— | |
| Change in cash | 6.3+955%420% | 0.6r0.8—— | −2.5—−224% | −0.6—−53.9% | −2.7−372%— | 1.0−65.1%— | 2.8—— | −6.9—— | −16−661%— | 2.8—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 | Q4 FY2021to Dec 31, 2021 | Q3 FY2021to Sep 30, 2021 | Q2 FY2021to Jun 30, 2021 | Q1 FY2021to Mar 31, 2021 | Q4 FY2020to Dec 31, 2020 | Q3 FY2020to Sep 30, 2020 | Q2 FY2020to Jun 30, 2020 | Q1 FY2020to Mar 31, 2020 | Q4 FY2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 3.7+1459%100% | 0.7+183%100% | 0.8—100% | 1.0—100% | 1.3*—100% | 0.2—100% | 0−100%— | 0−100%— | 0r0*−100%— | 0r0.0—— | 0.1—100% | 0.2—100% | 0.4r0.2*—100% | |
| Cost of revenue | 1.1+846%29.7% | 0.2+46.1%25.3% | 0.2—26.1% | 0.4—35.4% | 0.4*—29.8% | 0.1—49.0% | 0—— | 0—— | 0*—— | 0—— | — | — | — | |
| Gross profit | 2.6+2049%70.3% | 0.5+316%74.7% | 0.6—73.9% | 0.6—64.6% | 0.9*—70.2% | 0.1—51.0% | 0—— | 0—— | 0*—— | 0—— | — | — | — | |
| Research and development | 10+42.3%271% | 0.2−93.3%34.4% | 1.0−46.4%127% | 3.2+217%325% | 5.6*+637%444% | 3.4−21.6%1452% | 1.8r0.1+968%— | 1.0r0.1+369%— | 0.8r0.2*+168%— | 4.4r0.1—— | 0.2—269% | 0.2—140% | 0.3*—76.2% | |
| Selling and marketing | 0.1+333%3.3% | 0.0−42.6%2.0% | 0.0—2.5% | 0.0+1225%3.7% | 0.1*+2120%4.3% | 0.0—9.8% | 0—— | 0.0—— | 0.0*—— | 0—— | — | — | — | |
| General and administrative | 13−27.2%354% | 1.8−71.4%269% | 2.4−46.1%316% | 4.0−4.5%399% | 4.9*+64.4%388% | 6.3+253%2666% | 4.5r0.6+829%— | 4.2r0.4+990%— | 3.0r0.6*+701%— | 1.8r0.7—— | 0.5—767% | 0.4—245% | 0.4*—99.9% | |
| Operating expenses | 91+263%2462% | 2.0−79.0%305% | 3.4−45.9%445% | 7.3+39.7%727% | 78*+2006%6242% | 9.8+58.2%4128% | 6.3r0.7+865%— | 5.2r0.6+765%— | 3.7r0.8*+471%— | 6.2r0.8—— | 0.7—1036% | 0.6—385% | 0.6*—176% | |
| Operating income | −88—−2392% | −1.5—−231% | −2.9—−371% | −6.6—−663% | −77*—−6172% | −9.6—−4077% | −6.3r−0.7—— | −5.2r−0.6—— | −3.7r−0.8*—— | −6.2r−0.8—— | −0.6—−936% | −0.4—−285% | −0.3r−0.5*—−76.1% | |
| Other non-operating income (expense) | −3.7—−99.3% | −1.8—−270% | −0.6—−82.9% | −1.1—−115% | −0.1*—−5.4% | −3.1−728%−1306% | −0.3r0.0−231%— | −0.1r0.0—— | −0.5r0.1*—— | 0.5r0.0—— | 0.2—341% | −0.2—−101% | −0.4r−0.7*—−114% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—— | 0—— | 0*—— | 0—— | 0—0.0% | 0—0.0% | 0*—0.0% | |
| Income from discontinued operations | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0.0—0.0% | 0—— | 0—— | 0*—— | 0—— | — | — | — | |
| Net income including minority interests | −92—−2491% | −3.4—−501% | −3.5—−454% | −7.8—−778% | −77*—−6177% | −13—−5384% | −6.6r−0.7—— | −5.3r−0.5—— | −4.2r−0.7*—— | −5.7r−0.8—— | −0.4—−595% | −0.6—−386% | −0.7r−1.2*—−190% | |
| Minority interests' share of net income | −0.0—−0.7% | −0.0—−1.2% | −0.0—−0.4% | −0.0—−0.3% | −0.0*—−0.9% | −0.0—−5.7% | 0r−0.0—— | 0r−0.0—— | 0r−0.0*−100%— | 0r−0.0—— | −0.0—−10.6% | −0.0—−8.5% | 0.0*—1.9% | |
| Net income attributable to shareholders | −92—−2490% | −3.3—−499% | −3.5—−454% | −7.8—−777% | −77*—−6177% | −13—−5378% | −6.6r−0.7—— | −5.3r−0.5—— | −4.2r−0.7*—— | −5.7r−0.7—— | −0.4—−585% | −0.6—−377% | −0.7r−1.2*—−192% | |
| Earnings per share, basic | — | -0.07—— | -0.07—— | -0.20—— | — | -0.47—— | -0.27r-0.04—— | -0.22r-0.04—— | — | -1.84r-0.06—— | -0.03—— | -0.05—— | — | |
| Earnings per share, diluted | — | — | — | — | — | -0.47—— | -0.04—— | -0.04—— | — | -1.84r-0.06—— | -0.03—— | -0.05—— | — | |
| Shares, weighted average (basic) | 50+85.8%— | 50+85.8%— | 50+101%— | 38+56.6%— | — | 27—— | 25—— | 24—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | 27+777%— | 15+29.5%— | 14+25.3%— | — | 3.1r13—— | 12—— | 11—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.5—4.0% | 0.5−94.5%4.0% | 0.6−96.0%4.1% | 0.2−98.9%1.1% | 1.8+211%8.7% | 9.2+239%9.4% | 14+304%99.6% | 14+1256%97.7% | 0.6r1.9−47.3%57.4% | 2.7—84.2% | 3.4—83.6% | 1.1—56.8% | 1.1—55.3% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0.2—1.2% | 0.2−32.5%1.3% | 0.1—0.6% | 0.2−25.5%0.2% | 0−100%0.0% | 0.3−26.7%1.8% | 0r0.3−100%0.0% | 0.3—9.7% | 0.4—8.8% | 0.4—19.3% | 0.5—22.2% | |
| Receivables | 0.2—1.4% | 0.2+27.1%1.4% | 0.2—1.6% | 0.2—1.5% | 0.2—1.0% | 0.1+6.7%0.1% | 0−100%0.0% | — | 0r0.0−100%0.0% | 0.1—4.2% | 0.2—6.0% | 0.3—17.9% | 0.4—18.6% | |
| Other current assets | 0.2—1.9% | 0.2−76.2%1.9% | 0.3+519%2.1% | 0.3+363%2.4% | 0.8+32776%4.0% | 1.0+1805%1.1% | 0.0−17.5%0.3% | 0.1−12.4%0.5% | 0.0r0.0−94.4%0.2% | 0.1—1.7% | 0.1—1.4% | 0.1—4.3% | 0.0—2.2% | |
| Current assets | 1.2—9.5% | 1.2−90.9%9.5% | 1.7−87.9%12.3% | 1.4−90.2%10.6% | 4.1+348%19.6% | 13+313%13.6% | 14+240%100.0% | 15+701%100.0% | 0.9r2.3−53.8%89.4% | 3.2—99.8% | 4.1—99.8% | 1.8—98.3% | 2.0—98.3% | |
| Property, plant and equipment | 0.1—0.8% | 0.1−10.7%0.8% | 0.2+3623%1.4% | 0.2+3185%1.5% | 0.2+2223%1.0% | 0.1+1771%0.1% | 0.0−46.3%0.0% | 0.0−50.6%0.0% | 0.0r0.0−44.0%0.8% | 0.0—0.2% | 0.0—0.2% | 0.0—0.7% | 0.0—0.8% | |
| Right-of-use (leased) assets | 0.9—7.2% | 0.9+8.8%7.2% | 1.1—7.8% | 1.1—8.3% | 1.0+854%4.6% | 0.8—0.9% | — | — | 0.1—9.8% | — | — | — | — | |
| Goodwill | 9.3—72.7% | 9.3−88.0%72.7% | 9.3—68.4% | 9.3—68.6% | 9.3—43.8% | 77—78.5% | — | — | 0—0.0% | — | — | — | — | |
| Other intangible assets | 1.2—9.7% | 1.2−21.3%9.7% | 1.4—10.0% | 1.5—10.9% | 1.6—7.5% | 1.6—1.6% | — | — | 0—0.0% | — | — | — | — | |
| Total assets | 13—100% | 13−87.0%100% | 14−2.1%100% | 14−8.1%100% | 21+1944%100% | 98+2934%100% | 14+239%100% | 15+688%100% | 1.0r2.3−49.2%100% | 3.2—100% | 4.1—100% | 1.9—100% | 2.0—100% | |
| Accounts payable | 8.1—63.8% | 8.1+155%63.8% | 8.1+13240%59.6% | 6.7+2078%49.9% | 4.0+249%18.7% | 3.2+1037%3.3% | 0.1−79.9%0.4% | 0.3+16.4%2.1% | 1.1r0.2+331%110% | 0.3—8.7% | 0.3—7.4% | 0.3—14.3% | 0.3—12.9% | |
| Current liabilities | 22—174% | 22+118%174% | 20—145% | 15—112% | 11+143%53.1% | 10+2005%10.4% | — | — | 4.6r0.3+339%446% | 0.5—15.0% | 0.8—19.3% | 1.1—58.2% | 1.1r1.5—51.7% | |
| Lease liabilities (non-current) | 0.7—5.4% | 0.7−7.0%5.4% | 0.8—5.9% | 0.9—6.4% | 0.8+1045%3.8% | 0.7—0.8% | — | — | 0.1—6.8% | — | — | — | — | |
| Total liabilities | 23—180% | 23−3.9%180% | 20+6707%151% | 16+2977%118% | 23+383%107% | 24+4827%24.3% | 0.3−61.8%2.2% | 0.5−52.3%3.5% | 4.7r0.3+346%453% | 0.5—15.0% | 0.8—19.3% | 1.1—58.2% | 1.1r1.5—51.7% | |
| Retained earnings | −144—−1130% | −144—−1130% | −141—−1039% | −137—−1016% | −129—−612% | −52—−53.3% | −170—−1232% | −170—−1154% | −169—−16331% | −168—−5212% | −168—−4110% | −167—−8972% | −167r−167—−8184% | |
| Shareholders' equity | −10—−80.3% | −10−114%−80.3% | −7.0−182%−51.6% | −2.5−127%−18.4% | −1.6—−7.4% | 74—75.6% | 8.6—62.0% | 9.2—62.7% | −3.0—−286% | −2.2—−68.8% | −1.7—−41.9% | −4.2—−226% | −4.1r−4.5—−199% | |
| Minority interests | 0.1—0.6% | 0.1+1.1%0.6% | 0.1−98.6%0.5% | 0.1−99.0%0.4% | 0.1−98.8%0.3% | 0.1−98.5%0.1% | 5.0−0.8%35.9% | 5.0−0.6%33.8% | 5.0−1.3%480% | 5.0—154% | 5.0—123% | 5.0—268% | 5.0—247% | |
| Total equity | −10—−79.8% | −10−114%−79.8% | −6.9−105%−51.1% | −2.4−102%−18.0% | −1.5−101%−7.1% | 74r74−49.8%75.7% | 144r14+4284%1044% | 151r14+19265%1027% | 143r2.0—13857% | 148r2.7—4573% | 3.3—80.7% | 0.8—41.8% | −4.2r0.5—−207% | |
| Total liabilities and equity | 13—100% | 13−87.0%100% | 14−2.1%100% | 14−8.1%100% | 21+1944%100% | 98+2934%100% | 14+239%100% | 15+688%100% | 1.0r2.3−49.2%100% | 3.2—100% | 4.1—100% | 1.9—100% | 2.0—100% | |
| Shares outstanding | 51—— | 51+58.1%— | 50+221%— | 50+223%— | 35+165%— | 32+147%— | 15+19.7%— | 15+35.7%— | 13+18.4%— | 13—— | 13—— | 11—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | 0.0*−58.1%— | 0.0−38.9%— | 0.0*−23.7%— | 0.0*—— | 0.0*—4.5% | 0.0—2.0% | 0.0*—0.9% | |
| Share-based compensation | — | — | — | 0.5−75.1%45.4% | 1.1*−61.0%88.1% | 1.2*—498% | 2.0*—— | 1.8—— | 2.8r0*—— | — | — | — | — | |
| Cash from operating activities | −12—−328% | −0.8*—−120% | −0.2*—−21.9% | −3.8—−377% | −7.4r−8.1*−324%−589% | −15r−19*—−6435% | −3.0r−0.9*—— | −2.6r−0.4—— | 3.3r−0.8*—— | −7.5r−0.7*—— | −0.5*—−753% | −0.4—−273% | −0.4*—−98.8% | |
| Capital expenditure | −0.1—−2.8% | 0*—0.0% | 0*—0.0% | −0.0—−0.6% | −0.1*—−7.7% | −0.1*—−26.7% | −0.0*—— | −0.0—— | −0.0*—— | — | — | — | — | |
| Cash from investing activities | −0.1−101%−2.8% | 0*−100%0.0% | 0*−100%0.0% | −0.0—−0.6% | −0.1*—−7.7% | 13r13*—5515% | 0.5r0.3*—— | −0.0r0.1—— | −0.0r0.0*—— | −0.0r−0.0*—— | — | — | −0.0*—−0.5% | |
| Debt issued | — | 0*—0.0% | — | — | — | −0.2*—−84.6% | — | — | — | — | — | — | — | |
| Shares issued | 8.1+535%219% | 0*−100%0.0% | −0.1*—−6.7% | 6.5—647% | 1.7r7.3*—133% | 5.7r0*—2404% | 0*—— | 0—— | −4.4*—— | — | — | — | — | |
| Shares bought back | — | — | — | −0.1—−5.1% | — | — | — | 0—— | — | — | — | — | — | |
| Cash from financing activities | −1.6−109%−43.3% | 0.7*+5.9%106% | 0.5*−97.2%65.1% | −2.9−234%−290% | 0.1r0.9*—7.2% | 0.7r7.4*−87.8%284% | 18r0.0*+549%— | 2.2r13+464%— | −3.0r0*—— | 5.5r0*—— | 2.8*—4400% | 0.4—245% | — | |
| Exchange-rate effect on cash | — | — | — | — | — | −0.0*−141%−4.1% | 0.0*+3481%— | −0.0—— | −0.0r0.0*−662%— | 0.0r−0.0*—— | 0.0*—0.4% | −0.0—−15.3% | 0.0*—1.3% | |
| Change in cash | −14−199%−372% | −0.0*—−7.1% | 0.4*−97.4%52.2% | −6.7—−671% | −7.4*−2793%−589% | −1.5r1.8*—−636% | 16r−0.6*+562%— | −0.4r12—— | 0.3r−0.8*—— | −2.0r−0.7*—— | 2.4*—3716% | −0.1—−43.1% | −0.4*—−97.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2022. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Cleveland BioLabs#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Delisting notice 8 · Auditor changed 3 · Debt called early 2 · Directors and officers 6 · Material agreement 9 · New debt 2 · Unregistered share sale 4 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Delisting noticeMaterial agreement | 8-K | |
| Delisting notice | 8-K | |
| Auditor changed | 8-K/A | |
| Delisting noticeDirectors and officersMaterial agreementUnregistered share sale | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Delisting noticeDebt called earlyMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Delisting notice | 8-K/A | |
| Delisting noticeDebt called earlyDirectors and officers | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K/A | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K/A | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Feb 1, 2023
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $2 M | No. 5 | Under $2 million | 3 | equity, options | SEC |
| Dec 2015 | $1 M | No. 4 | Under $2 million | 1 | equity | SEC |
| Jul 2015 | $25 M | No. 3 | $10 to $50 million | 1 | equity | SEC |
| Jun 2014 | $4 M | No. 2 | $2 to $10 million | 3 | equity, options | SEC |
| Mar 2010 | $5 M | No. 1 | $2 to $10 million | 9 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Cleveland BioLabs compares in Biotechnology
- Revenue$1 M · higher than 28% of 647
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cleveland BioLabs🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2021
- Balance sheet:
- As of December-2021
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, Wikipedia, Wikimedia Commons, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cleveland BioLabs? Verify and update this profile — free
Show Cleveland BioLabs's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.